We further tested Trametinib, another potent and highly specific MEK1 inhibitor, an FDA‐approved drug for the treatment of melanoma (Yamaguchi, Kakefuda, Tajima, Sowa, & Sakai, 2011). This evidence concerns the gene MAP2K1 and melanoma.